Vivaldi Biosciences Inc. Signs Cooperative Research And Development Agreement (CRADA) With National Institute of Allergy And Infectious Diseases (NIAID) To Develop Live Attenuated Influenza Vaccine Against Influenza H7N9

Published: Jan 21, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

FORT COLLINS, Colo.--(BUSINESS WIRE)--Vivaldi Biosciences Inc., a clinical-stage biotechnology company developing live attenuated influenza vaccines (LAIVs) against seasonal and pandemic influenza, today announced that it has signed a Cooperative Research and Development Agreement (CRADA) with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to generate and evaluate in preclinical studies LAIV candidates against influenza A(H7N9). The H7N9 strain is of concern due to its pandemic potential. Human cases of this avian-origin influenza strain were first recognized in early 2013.

Help employers find you! Check out all the jobs and post your resume.

Back to news